Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efavirenz + indinavir
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Efavirenz + indinavir is a combination antiretroviral therapy used in the management of HIV infection.** Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to and inhibits HIV-1 reverse transcriptase, thereby preventing the conversion of viral RNA into DNA, essential for viral replication[1][6]. Indinavir is a protease inhibitor that binds to the HIV-1 protease enzyme, preventing the cleavage of viral polyproteins and inhibiting the maturation of infectious viral particles[2][4]. Together, they act on distinct stages of the HIV replication cycle, providing synergistic antiviral activity when used as part of combination therapy for HIV.
- Brand names
- efavirenz + indinavir
- Other names
- efavirenz + indinavir
02
Targets
Human immunodeficiency virus type 1 reverse transcriptasePR (Progesterone receptor)
Beyond the preview
Go deeper on efavirenz + indinavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efavirenz + indinavir.